Atlanta, United States
Neurogram™, founded in 2021, operates at the intersection of AI and health care with a primary focus on neurological research. The company’s mission, encapsulated in its slogan, "Auxiliamos a comunidade médica a investigar o cérebro humano com Inteligência Artificial," reflects its dedication to assisting the medical community in brain research using AI innovations.
Headquartered in the United States with locations in Atlanta and São Paulo, Neurogram™ is progressing with both approved and developmental products. Its successful ANVISA-approved offerings include a SaaS platform for EEG visualization and an AI for sleep disorder biomarkers developed with the Instituto do Sono. Currently, it is collaborating with the Mayo Clinic on an AI for Neuro-ICU biomarkers.
The startup received a Seed Round investment on 01 January 2023, led by Starship Ventures. This backing is part of support from esteemed health-focused funds including Caffeinated Capital and Z Fellows. Furthermore, its participation in Google for Startups suggests a strong growth trajectory and innovation potential within the highly competitive health tech industry.
